Syros Pharmaceuticals, Inc. (SYRS) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 386K | 3.76M | 2.83M | 2.95M | -5.47M | 3.89M | 6.28M | 5.47M | 7.8M |
| Revenue Growth % | -100% | -100% | -100% | 107.06% | -3.32% | -54.86% | -45.97% | -170.07% | -31.7% | 21.58% | 13.26% | 36.9% |
| Cost of Goods Sold | 325K | 331K | 334K | 279K | 616K | 653K | 704K | 770K | 724K | 726K | 747K | 0 |
| COGS % of Revenue | - | - | - | 72.28% | 16.37% | 23.05% | 23.83% | -14.08% | 18.61% | 11.57% | 13.66% | - |
| Gross Profit | -325K | -331K | -334K | 107K | 3.15M | 2.18M | 2.25M | -6.24M | 3.17M | 5.55M | 4.72M | 7.8M |
| Gross Margin % | - | - | - | 27.72% | 83.63% | 76.95% | 76.17% | 114.08% | 81.39% | 88.43% | 86.34% | 100% |
| Gross Profit Growth % | -110.33% | -115.18% | -114.84% | 101.72% | -0.66% | -60.72% | -52.33% | -179.94% | -44.41% | 7.52% | -2.22% | 36.9% |
| Operating Expenses | 26.18M | 27.42M | 30.59M | 27.11M | 38.4M | 36.83M | 36.17M | 35.24M | 33.84M | 40.05M | 32.12M | 33.23M |
| OpEx % of Revenue | - | - | - | 7023.83% | 1020.68% | 1300.14% | 1224.31% | -644.65% | 869.57% | 638.07% | 587.53% | 425.85% |
| Selling, General & Admin | 5.66M | 5.46M | 6.27M | 5.89M | 7.76M | 7.22M | 7.41M | 7.33M | 8.08M | 6.95M | 6.95M | 6.43M |
| SG&A % of Revenue | - | - | - | 1525.39% | 206.38% | 255.03% | 250.68% | -134.06% | 207.56% | 110.66% | 127.11% | 82.41% |
| Research & Development | 20.53M | 21.95M | 24.32M | 21.22M | 28.28M | 29.61M | 28.76M | 27.91M | 25.76M | 33.1M | 25.17M | 26.8M |
| R&D % of Revenue | - | - | - | 5498.45% | 751.73% | 1045.11% | 973.63% | -510.59% | 662.01% | 527.41% | 460.42% | 343.44% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 1000K | 0 | 0 | 1000K | -1000K | 0 | 0 | 0 |
| Operating Income | -26.18M | -27.42M | -30.92M | -27M | -34.64M | -34M | -33.21M | -36M | -39.45M | -33.77M | -26.65M | -25.42M |
| Operating Margin % | - | - | - | -6996.11% | -920.68% | -1200.14% | -1124.31% | 658.44% | -1013.98% | -538.07% | -487.53% | -325.85% |
| Operating Income Growth % | 24.41% | 19.36% | 6.9% | 24.98% | 12.21% | -0.68% | -24.61% | -41.59% | -46.61% | -29.17% | -27.28% | 12.99% |
| EBITDA | -25.86M | -27.09M | -30.59M | -26.73M | -34.02M | -33.35M | -32.51M | -35.23M | -38.73M | -33.04M | -25.91M | -24.65M |
| EBITDA Margin % | - | - | - | -6923.83% | -904.31% | -1177.09% | -1100.47% | 644.36% | -995.37% | -526.5% | -473.86% | -315.94% |
| EBITDA Growth % | 23.99% | 18.78% | 5.91% | 24.13% | 12.16% | -0.92% | -25.48% | -42.91% | -48.14% | -30.12% | -28.18% | 13.36% |
| D&A (Non-Cash Add-back) | 325K | 331K | 334K | 279K | 616K | 653K | 704K | 770K | 724K | 726K | 747K | 773K |
| EBIT | -5.08M | -21.95M | -2.4M | -63.05M | -38.84M | -34.98M | -22.57M | -3.65M | -29.2M | -33.5M | -24.17M | -22.83M |
| Net Interest Income | -519K | -297K | 239K | -46K | 330K | 847K | 558K | 467K | -659K | -869K | -941K | -955K |
| Interest Income | 793K | 1.08M | 1.55M | 1.28M | 1.63M | 2.13M | 1.77M | 1.59M | 392K | 112K | 35K | 31K |
| Interest Expense | 1.31M | 1.38M | 1.31M | 1.33M | 1.3M | 1.28M | 1.22M | 1.13M | 1.05M | 981K | 976K | 986K |
| Other Income/Expense | 19.79M | 4.09M | 27.21M | -37.24M | -5.51M | -2.26M | 9.42M | 31.22M | 9.2M | -712K | 1.51M | 1.61M |
| Pretax Income | -6.4M | -23.33M | -3.71M | -64.38M | -40.14M | -36.26M | -23.79M | -4.77M | -30.25M | -34.48M | -25.15M | -23.81M |
| Pretax Margin % | - | - | - | -16679.79% | -1067.07% | -1279.84% | -805.31% | 87.32% | -777.51% | -549.41% | -459.96% | -305.22% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -6.4M | -23.33M | -3.71M | -64.38M | -40.14M | -36.26M | -14.92M | 27.57M | -21.05M | -35.19M | -23.64M | -23.81M |
| Net Margin % | - | - | - | -16679.79% | -1067.07% | -1279.84% | -505.21% | -504.39% | -541.04% | -560.76% | -432.39% | -305.22% |
| Net Income Growth % | 84.07% | 35.66% | 75.15% | -333.49% | -90.69% | -3.03% | 36.87% | 215.8% | 19.11% | -56.48% | -66.14% | 20.97% |
| Net Income (Continuing) | -6.4M | -23.33M | -3.71M | -64.38M | -40.14M | -36.26M | -23.79M | -4.77M | -30.25M | -34.48M | -25.15M | -23.81M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.16 | -0.59 | -0.10 | -2.18 | -1.43 | -1.30 | -0.54 | 0.99 | -2.24 | -5.51 | -3.75 | -3.78 |
| EPS Growth % | 88.81% | 54.62% | 82.39% | -320.2% | 36.16% | 76.41% | 85.6% | 126.19% | 45.89% | -53.91% | -61.64% | 23.01% |
| EPS (Basic) | -0.16 | -0.59 | -0.10 | -2.18 | -1.43 | -1.30 | -0.54 | 0.99 | -2.24 | -5.51 | -3.75 | -3.78 |
| Diluted Shares Outstanding | 39.34M | 39.27M | 38.98M | 29.54M | 27.99M | 27.91M | 27.84M | 27.75M | 9.42M | 6.38M | 6.31M | 6.29M |
| Basic Shares Outstanding | 39.27M | 39.27M | 38.98M | 29.54M | 27.99M | 27.91M | 27.84M | 27.75M | 9.42M | 6.38M | 6.31M | 6.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |